I. Dogan Et Al. , "Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.," JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022
Dogan, I. Et Al. 2022. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16 .
Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A., (2022). Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.
Dogan, İzzet Et Al. "Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.," JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022
Dogan, İzzet Et Al. "Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022
Dogan, I. Et Al. (2022) . "Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.
@article{article, author={İzzet DOĞAN Et Al. }, title={Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2022}